Targeting and Inhibiting Plasmodium falciparum Using Ultra-small Gold Nanoparticles

ACS Appl Mater Interfaces. 2020 Sep 30;12(39):43380-43387. doi: 10.1021/acsami.0c09075. Epub 2020 Sep 16.

Abstract

Malaria, a mosquito-borne disease caused by Plasmodium species, claims more than 400,000 lives globally each year. The increasing drug resistance of the parasite renders the development of new anti-malaria drugs necessary. Alternatively, better delivery systems for already marketed drugs could help to solve the resistance problem. Herein, we report glucose-based ultra-small gold nanoparticles (Glc-NCs) that bind to cysteine-rich domains of Plasmodium falciparum surface proteins. Microscopy shows that Glc-NCs bind specifically to extracellular and all intra-erythrocytic stages of P. falciparum. Glc-NCs may be used as drug delivery agents as illustrated for ciprofloxacin, a poorly soluble antibiotic with low antimalarial activity. Ciprofloxacin conjugated to Glc-NCs is more water-soluble than the free drug and is more potent. Glyco-gold nanoparticles that target cysteine-rich domains on parasites may be helpful for the prevention and treatment of malaria.

Keywords: Plasmodium falciparum; ciprofloxacin; gold nanoparticles; inhibition; targeting.

MeSH terms

  • Antimalarials / chemistry
  • Antimalarials / pharmacology*
  • Ciprofloxacin / chemistry
  • Ciprofloxacin / pharmacology*
  • Glucose / chemistry
  • Gold / chemistry*
  • Metal Nanoparticles / chemistry*
  • Molecular Structure
  • Parasitic Sensitivity Tests
  • Particle Size
  • Plasmodium falciparum / drug effects*
  • Surface Properties

Substances

  • Antimalarials
  • Ciprofloxacin
  • Gold
  • Glucose